Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026 GlobeNewswire December 08, 2025 Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint […]

Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults GlobeNewswire December 08, 2025 Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines Through Head-to-Head

OR Royalties Announces Renewal of Normal Course Issuer Bid Year-To-Date 2025: 593,432 Shares Repurchased for C$28.0 Million GlobeNewswire December 08, 2025 MONTREAL, Dec. 08, 2025 (GLOBE NEWSWIRE) — OR Royalties Inc. (the “Company” or “OR Royalties“) (OR: TSX & NYSE) is pleased to announce that the Toronto Stock Exchange (the “TSX“) has approved the Company's

Ocular Therapeutix(TM) Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI(TM) in Wet AMD GlobeNewswire December 08, 2025 Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive SOL-1 topline data remain on track for 1Q 2026 Ocular plans to leverage the 505(b)(2) regulatory

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia GlobeNewswire December 08, 2025 CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has not yet issued

14 G/T Au Within 47m of Gold-Bearing Skarn from 26m Depth in 300m Step-Out at Birch Cu-Au Project GlobeNewswire December 08, 2025 VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) — Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) (“Yukon Metals” or the “Company“) is pleased to announce results from the last two holes

Gaming and Leisure Properties Expands Board of Directors With Appointment of Michael Borofsky GlobeNewswire December 08, 2025 WYOMISSING, Pa., Dec. 08, 2025 (GLOBE NEWSWIRE) — Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) (the “Company”), announced today that Michael Borofsky has been appointed to the Board of Directors as a new independent director, effective immediately, subject

eToro Group Reports Selected November Business Metrics GlobeNewswire December 08, 2025 NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) — eToro Group Ltd. (“eToro”, or the “Company”) (NASDAQ: ETOR), the trading and investing platform, is reporting the below selected monthly business metrics for November 2025. Assets under Administration (AUA) were $18.8B, up 9% year-over-year. Funded accounts

Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference GlobeNewswire December 08, 2025 SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at

Montara Therapeutics Announces Development Candidate for First BrainOnly(TM)-Enabled Program in TSC-Related Epilepsy and Appoints Chief Business Officer GlobeNewswire December 08, 2025 Montara's BrainOnly platform is designed to prevent peripheral side effects and concentrate neurological drugs' activity in the brain via two-drug combination therapies, comprising its non-brain-penetrant “universal” peripheral blocker development candidate, MT1110, and a brain-penetrant